BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3540993)

  • 1. OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments.
    Goldstein G; Norman DJ; Shield CF; Kreis H; Burdick J; Flye MW; Rivolta E; Starzl T; Monaco A
    Prog Clin Biol Res; 1986; 224():239-49. PubMed ID: 3540993
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
    Monaco A; Goldstein G; Barnes L
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized trial comparing the efficacy of OKT3 used to prevent or to treat rejection.
    Kreis H; Chkoff N; Chatenoud L; Debure A; Lacombe M; Chrétien Y; Legendre C; Caillat S; Bach JF
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1741-4. PubMed ID: 2652570
    [No Abstract]   [Full Text] [Related]  

  • 4. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.
    Kremer AB; Barnes L; Hirsch RL; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):54-7. PubMed ID: 3105141
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical development of Orthoclone OKT3.
    Cosimi AB
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
    [No Abstract]   [Full Text] [Related]  

  • 6. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
    Chatenoud L; Bach JF
    Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of monoclonal antibodies to T cells (OKT3) for treatment of acute cellular rejection after renal transplantation.
    Birkeland SA; Svendsen V; Rohr N; Hansen BL; Elbirk A; Foged N; Køhler F
    Transplant Proc; 1988 Jun; 20(3):451-4. PubMed ID: 3289183
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoclonal antibody (OKT3) rescue in refractory acute renal allograft rejection: report of 3 cases.
    Suvanapha R; Laorpatanaskul S; Vajaraphongse R; Kitisin P; Srivatanawongsa V; Mulikamas S; Vajaraphongse K; Boonvisut S; Chusil S; Panmuong W
    J Med Assoc Thai; 1989 Dec; 72(12):708-13. PubMed ID: 2628539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orthoclone OKT3 treatment of acute renal allograft rejection.
    Friedman J; Barnes L; Sheahan M; Tsai H; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 2):46. PubMed ID: 3105144
    [No Abstract]   [Full Text] [Related]  

  • 10. Monoclonal antibodies to human T cell subsets: use for immunological monitoring and immunosuppression in renal transplantation.
    Burton RC; Cosimi AB; Colvin RB; Rubin RH; Delmonico FL; Goldstein G; Russell PS
    J Clin Immunol; 1982 Jul; 2(3 Suppl):142S-147S. PubMed ID: 6290526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of progressive renal allograft dysfunction with OKT3.
    Burdick JF; Pennington LR; Smith W; Irwin B; Williams GM
    Nephron; 1987; 46 Suppl 1():52-5. PubMed ID: 2957603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into therapy with monoclonal antibodies in allograft transplantation.
    Schena FP
    Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation.
    De Pauw L; Abramowicz D; Goldman M; Vereerstraeten P; Kinnaert P; Toussaint C
    Transplant Proc; 1990 Aug; 22(4):1759-60. PubMed ID: 2117800
    [No Abstract]   [Full Text] [Related]  

  • 14. CD4 monoclonal antibodies in the preclinical dog renal allograft model.
    Watson CJ; Davies HS; Metcalfe SM; Cobbold SP; Rebello PR; Collier DS; Waldmann H; Calne RY
    Transplant Proc; 1993 Feb; 25(1 Pt 1):804-6. PubMed ID: 8438491
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibody.
    Waid TH; Lucas BA; Thompson JS; Brown S; Moore D; Amlot P; Janossy G
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1778-84. PubMed ID: 2652582
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
    Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
    [No Abstract]   [Full Text] [Related]  

  • 17. Infection in OKT3-treated patients receiving additional antirejection therapy.
    Munda R; Hutchins M; First MR; Carey M; Schroeder T; Alexander JW
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1763-5. PubMed ID: 2652577
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine.
    Thistlethwaite JR; Haag BW; Gaber AO; Stuart JK; Aronson AJ; Mayes JT; Lloyd DM; Stuart FP
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1901-4. PubMed ID: 3103294
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.
    Ortho Multicenter Transplant Study Group
    N Engl J Med; 1985 Aug; 313(6):337-42. PubMed ID: 2861567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring immunosuppression following renal transplantation.
    Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
    Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.